Eli Lilly and Company (NYSE:LLY) is expected to pay $0.51 on Dec 9, 2016. The indicated annual dividend is $2.04. Shareholders owning the stock before Nov 10, 2016 will be eligible to receive the payout. Based on Eli Lilly and Company’s current price of $74.02, the dividend is 0.69%. This dividend’s record date is Nov 15, 2016 and the announcement date is Oct 18, 2016. The stock increased 0.19% or $0.14 during the last trading session, hitting $74.02. About 4,377 shares traded hands. Eli Lilly and Co (NYSE:LLY) has declined 0.76% since April 7, 2016 and is downtrending. It has underperformed by 5.55% the S&P500.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $83.28 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 32.14 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.36, from 0.71 in 2016Q1. The ratio is positive, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Gabelli Funds Limited Com has invested 0.26% of its portfolio in Eli Lilly and Co (NYSE:LLY). West Family Invests reported 18,000 shares or 0.26% of all its holdings. Evercore Wealth Mngmt Llc holds 25,139 shares or 0.09% of its portfolio. Quantitative Systematic Strategies Ltd Liability Corp owns 10,243 shares or 0.37% of their US portfolio. Clinton Gp owns 51,776 shares or 0.18% of their US portfolio. New England Rech & Mgmt has 0.5% invested in the company for 7,400 shares. Moreover, Advisory Serv has 0.17% invested in Eli Lilly and Co (NYSE:LLY) for 5,974 shares. Bremer Tru Natl Association has 0.08% invested in the company for 3,514 shares. Regions Fin Corp accumulated 544,298 shares or 0.56% of the stock. Reynders Mcveigh Capital Mgmt Ltd Liability has 7,104 shares for 0.08% of their US portfolio. Hyman Charles D accumulated 5,300 shares or 0.06% of the stock. Krasney Ltd Liability Company holds 0.08% or 4,124 shares in its portfolio. Amica Retiree Tru has 0.39% invested in the company for 5,843 shares. Teachers Retirement Of The State Of Kentucky has invested 0.43% of its portfolio in Eli Lilly and Co (NYSE:LLY). Hanson & Doremus Invest Mgmt holds 0.15% or 4,298 shares in its portfolio.
Insider Transactions: Since May 12, 2016, the stock had 1 buy, and 10 sales for $120.57 million net activity. $17.13M worth of Eli Lilly and Co (NYSE:LLY) shares were sold by LILLY ENDOWMENT INC. 1,213 shares were sold by Zakrowski Donald A, worth $100,873. Barnes Melissa S sold 992 shares worth $73,180. Crowe Maria A sold $182,927 worth of stock. TAI JACKSON P had bought 2,560 shares worth $205,875 on Friday, August 12.
Eli Lilly and Co (NYSE:LLY) Ratings Coverage
Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was upgraded by BMO Capital Markets on Monday, November 16 to “Outperform”. Leerink Swann maintained it with “Outperform” rating and $101 target price in Monday, May 2 report. The stock has “Buy” rating given by Jefferies on Thursday, July 14. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, October 13 report. On Thursday, November 12 the stock rating was maintained by Leerink Swann with “Outperform”. On Tuesday, December 1 the stock rating was upgraded by Barclays Capital to “Overweight”. The rating was maintained by Leerink Swann on Monday, December 28 with “Outperform”. Deutsche Bank upgraded Eli Lilly and Co (NYSE:LLY) rating on Monday, December 7. Deutsche Bank has “Buy” rating and $99 price target. The rating was maintained by Argus Research on Tuesday, August 2 with “Buy”. The rating was maintained by Cowen & Co on Saturday, August 22 with “Outperform”.
More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Forbes.com which released: “Ex-Dividend Reminder: Eli Lilly, Teleflex and Chemed” on November 08, 2016, also Fool.com with their article: “Better Buy: Eli Lilly and Co vs. Pfizer” published on October 26, 2016, Seekingalpha.com published: “Eli Lilly & Co. (LLY) Q3 2016 Results – Earnings Call Transcript” on October 25, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Valuewalk.com and their article: “Merck & Co., Inc. Surges After Earnings, Eli Lilly and Co Slips” published on October 25, 2016 as well as Streetinsider.com‘s news article titled: “Eli Lilly & Co. (LLY) Announces Presentation of Baricitinib Phase 3 Data in RA …” with publication date: November 03, 2016.
LLY Company Profile
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.